2024
Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer
Yu J, DeStephano D, Jeffers B, Horowitz D, Soulos P, Gross C, Cheng S. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. Journal Of Clinical Oncology 2024, 42: 1943-1952. PMID: 38507655, DOI: 10.1200/jco.23.01604.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProton beam therapyGU toxicityProstate cancerGI toxicityBenefits of proton beam therapyIntensity-modulated radiation therapy patientsPBT patientsLocalized prostate cancerTreatment-related toxicityComparison of GIStatistically significant differenceRadiation therapyBeam therapySEER-MedicareToxicity of protonProcedure codesComparative effectiveness studiesObservational studyPatientsSignificant differenceCancerMonthsComparing GIProstate
2023
Physician-driven artificial intelligence enabled planning for intraprostatic dose escalation in under ten minutes.
Rayn K, Elliston C, Savacool M, Fang Y, Deutsch I, Spina C, Kachnic L, Yu J. Physician-driven artificial intelligence enabled planning for intraprostatic dose escalation in under ten minutes. Journal Of Clinical Oncology 2023, 41: 187-187. DOI: 10.1200/jco.2023.41.6_suppl.187.Peer-Reviewed Original ResearchTreatment planning systemIntraprostatic dose escalationDose escalationStatic IMRT plansDose escalation planTreatment planningIMRT plansVMAT plansSBRT plansPTV doseDosimetric parametersTreatment planning tasksStatic fieldRadiation dose escalationOARsPTVProstate dosePlanning systemIntraprostatic dosesArea of clinical interestProstate modelProstateAcceptable doseUnique patientsComplex treatment
2020
Association Between Percentage of Positive Biopsy Cores and Risk of Pelvic Lymph Node Involvement in Prostate Cancer
Yang D, Dee E, Arega M, Nguyen P, Orio P, King M, Kann B, Yu J, Sandler K, Ma T, Kishan A, Muralidhar V. Association Between Percentage of Positive Biopsy Cores and Risk of Pelvic Lymph Node Involvement in Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e860. DOI: 10.1016/j.ijrobp.2020.07.427.Peer-Reviewed Original Research
2019
Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancerComparative Effectiveness of SBRT
Aneja S, Kumar R, Yu J. Comparative Effectiveness of SBRT. 2019, 415-424. DOI: 10.1007/978-3-030-16924-4_34.Peer-Reviewed Original ResearchStereotactic body radiation therapyAlternative treatment modalityBody radiation therapyComparative effectiveness studiesCost-effectiveness studiesLarge database analysisRetrospective seriesTreatment modalitiesRadiation therapySBRT treatmentComparative effectivenessEffectiveness studiesDatabase analysisStereotactic treatmentTreatmentPatientsLungTherapyProstateLiverBrainModerate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer
Beckta J, Nosrati J, Yu J. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer. Urologic Oncology Seminars And Original Investigations 2019, 37: 619-627. PMID: 30738746, DOI: 10.1016/j.urolonc.2019.01.015.Peer-Reviewed Original ResearchConceptsModerate hypofractionationRadiation therapyStereotactic body radiation therapyProstate cancer radiation therapyTreatment of prostate cancerCancer radiation therapyReduced duration of treatmentDuration of treatmentStandard of careCurative intentProstate cancerHigh dosesHypofractionationReduced durationDaily sessionsFractionation schemeTherapyEffective alternativeTreatmentProstatePatientsCancerDoseMonthsCare
2017
Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery.
Yu J, Hamstra D. Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery. Oncology 2017, 31: 830-2, 835. PMID: 29179251.Peer-Reviewed Original ResearchProstate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance
Mahal A, Mahal B, Nguyen P, Yu J. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer 2017, 124: 752-759. PMID: 29084350, DOI: 10.1002/cncr.31106.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityMetastatic diseaseCancer-specific mortalityProstate cancer outcomesOutcomes of patientsMedicaid insuranceEnd Results ProgramReceipt of therapyStage of diseaseAfrican American patientsInsurance statusPrivately insured cohortDefinitive treatmentProstate cancerLocalized CaPResults ProgramPrivate insuranceCAP outcomesCancer outcomesAmerican patientsPatientsProstateRacial disparitiesAssociated with raceAssociated with racial disparitiesTrends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study.
Mahal B, Chen Y, Muralidhar V, Yang D, Mahal A, Yu J, Orio P, Nguyen P. Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study. Journal Of Clinical Oncology 2017, 35: e545-e545. DOI: 10.1200/jco.2017.35.6_suppl.e545.Peer-Reviewed Original ResearchStereotactic body radiotherapyLocalized prostate cancerNational Cancer Data BaseGrade prostate cancerProstate cancerLow-risk disease featuresNational Cancer Database studyExternal beam radiotherapyLong-term efficacyMultivariate logistic regressionBeam radiotherapyRadiotherapy useTherapy optionsClinical factorsMultivariable adjustmentHazard ratioAcademic centersDisease characteristicsRadiotherapyDisease featuresProstateDatabase studyCancerPatientsHigher stage
2016
The Effect of Race and Decision Aids on Physician Recommendation for Prostate Cancer Treatment Planning
Mahal A, Mahal B, Singh R, Green A, Nguyen P, Yu J. The Effect of Race and Decision Aids on Physician Recommendation for Prostate Cancer Treatment Planning. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e396. DOI: 10.1016/j.ijrobp.2016.06.1626.Peer-Reviewed Original ResearchRadiation Oncology Practice: Adjusting to a New Reimbursement Model.
Konski A, Yu J, Freedman G, Harrison L, Johnstone P. Radiation Oncology Practice: Adjusting to a New Reimbursement Model. JCO Oncology Practice 2016, 12: e576-83. PMID: 27006359, DOI: 10.1200/jop.2015.007385.Peer-Reviewed Original ResearchConceptsRelative value unitsRadiation oncologyTechnical revenueFee-for-service modelDeliver hypofractionated radiotherapyValue-based environmentRadiation oncology departmentsFee-for-serviceLung cancer casesHypofractionated radiotherapyHypofractionation usePalliative treatmentHypofractionationCancer casesPatient volumeLung cancerReimbursement modelsStaff timeOncology departmentValue unitsIncreasing skillsStaffProstateWorkforce predictionsPatientsNational trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study
Mahal B, Chen Y, Efstathiou J, Muralidhar V, Hoffman K, Yu J, Feng F, Beard C, Martin N, Orio P, Nguyen P. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer 2016, 122: 1505-1512. PMID: 26970022, DOI: 10.1002/cncr.29960.Peer-Reviewed Original ResearchConceptsProton therapy useProstate cancerProton therapyTherapy useIncreasing use of proton therapyMultivariable adjustmentUse of proton therapyNational Cancer Data BaseLong-term follow-upExternal beam radiotherapyMultivariate logistic regression analysisHigh-grade diseaseNonmetastatic prostate cancerFactors associated with receiptNationwide cancer registryLogistic regression analysisBeam radiotherapyDefinitive therapyOncological therapyNonacademic centersTreated patientsClinical factorsFollow-upProstateCancer Registry
2012
A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus From Prostate Cancer-specific Mortality to Distant Metastasis-free Survival
Dosoretz A, Lester-Coll N, Yu J. A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus From Prostate Cancer-specific Mortality to Distant Metastasis-free Survival. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s57. DOI: 10.1016/j.ijrobp.2012.07.355.Peer-Reviewed Original Research
2010
Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy.
Raldow A, Hamstra D, Kim S, Yu J. Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy. Oncology 2010, 24: 692-700, 702. PMID: 20718248.Peer-Reviewed Original ResearchConceptsSalvage radiation therapyAdjuvant radiation therapyRadical prostatectomyProstate cancerRadiation therapyPost-operative adjuvant radiation therapyBiochemical recurrence of prostate cancerImmediate adjuvant radiation therapySalvage external beam radiotherapyEvidence of recurrent diseaseRecurrence of prostate cancerExternal beam radiotherapyCause of cancer deathRadiotherapy volumeBeam radiotherapyBiochemical recurrenceRecurrent diseaseRandomized trialsCancer deathProstatectomySide effectsProstatePatientsCancerRadiotherapy